H.C. Wainwright analyst Yi Chen lowered the firm’s price target on Lexaria Bioscience (LEXX) to $4 from $5 and keeps a Buy rating on the shares after the company reported interim results from the Phase 1b GLP-1-H24-4 study currently underway in Australia. The firm says DehydraTECH-semaglutide has demonstrated a favorable safety and tolerability profile.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LEXX:
- Lexaria Bioscience Reports Promising Interim Results in GLP-1 Study
- Lexaria Bioscience provides interim results of Phase 1b GLP-1-H24-4 study
- Lexaria’s DehydraTECH Technology Poised to Transform GLP-1 Industry
- Lexaria Bioscience provides update on DehydraTECH technology
- Lexaria Bioscience price target lowered to $5 from $7 at H.C. Wainwright